A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

This study is testing whether adding an immunotherapy drug (serplulimab, which blocks a protein that prevents the immune system from attacking tumors) and an anti-blood vessel drug (bevacizumab) to standard XELOX chemotherapy improves outcomes in patients with metastatic colorectal cancer who have not yet been treated. **You may be eligible if...** - You have been confirmed to have unresectable (cannot be surgically removed) metastatic colorectal cancer - You have NOT received prior chemotherapy for your metastatic disease - If you received prior adjuvant (post-surgery) chemotherapy, it was completed more than 12 months ago - You have at least one measurable tumor on scans - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have previously received systemic chemotherapy for metastatic disease - You have active autoimmune disease or are on chronic steroids - You have had a serious bowel perforation or uncontrolled bleeding - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.